Abstract
Loss of the tumor suppressors FAT1 or RB1 promotes CDK4/6 inhibitor resistance in ER+ breast cancer.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
February 2019
Volume 9, Issue 2
Volume 9, Issue 2
Loss of FAT1 Drives Resistance to CDK4/6 Inhibitors in Breast Cancer
Jump to section
Advertisement